These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 32075584)
21. Trends of Body Mass Index changes among adults on antiretroviral therapy in Northwest Ethiopia: a longitudinal data analysis. Bantie B; Gebeyehu NA; Adella GA; Kassie GA; Mengstie MA; Abebe EC; Seid MA; Gesese MM; Tegegne KD; Anley DT; Zemene MA; Dessie AM; Feleke SF; Dejenie TA; Kebede YS; Chanie ES; Kerebeh G; Bayih WA; Moges N Sci Rep; 2024 Mar; 14(1):5265. PubMed ID: 38438418 [TBL] [Abstract][Full Text] [Related]
22. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698 [TBL] [Abstract][Full Text] [Related]
23. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA; Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427 [TBL] [Abstract][Full Text] [Related]
25. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A; J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529 [TBL] [Abstract][Full Text] [Related]
26. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. Eluwa GI; Badru T; Agu KA; Akpoigbe KJ; Chabikuli O; Hamelmann C BMC Clin Pharmacol; 2012 Feb; 12():7. PubMed ID: 22369677 [TBL] [Abstract][Full Text] [Related]
27. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H; Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China. Wu YS; Zhang WW; Ling XM; Yang L; Huang SB; Wang XC; Wu H; Cai WP; Wang M; Wang H; Liu YF; He HL; Wei FL; Wu ZY; Zhang FJ Chin Med J (Engl); 2016 Feb; 129(3):304-8. PubMed ID: 26831232 [TBL] [Abstract][Full Text] [Related]
29. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Popoola TD; Awodele O; Oshikoya KA Afr J Med Med Sci; 2016 Jun; 45(2):179-187. PubMed ID: 29465861 [TBL] [Abstract][Full Text] [Related]
30. Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study. Yu XD; Huang H; Jiao Y; Li J; Fan X; Zhang D; Wang FS Lipids Health Dis; 2023 Feb; 22(1):27. PubMed ID: 36823632 [TBL] [Abstract][Full Text] [Related]
31. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients]. Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757 [TBL] [Abstract][Full Text] [Related]
32. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. Law JKC; Butler LT; Hamill MM AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589 [TBL] [Abstract][Full Text] [Related]
33. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. TenoRes Study Group Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472 [TBL] [Abstract][Full Text] [Related]
34. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
35. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332 [TBL] [Abstract][Full Text] [Related]
36. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Castillo SA; Hernandez JE; Brothers CH Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966 [TBL] [Abstract][Full Text] [Related]
37. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609 [TBL] [Abstract][Full Text] [Related]
38. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Spaulding A; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777 [TBL] [Abstract][Full Text] [Related]
39. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M; Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468 [TBL] [Abstract][Full Text] [Related]
40. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. Zash R; Souda S; Chen JY; Binda K; Dryden-Peterson S; Lockman S; Mmalane M; Makhema J; Essex M; Shapiro R J Acquir Immune Defic Syndr; 2016 Apr; 71(4):428-36. PubMed ID: 26379069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]